Drug intelligence / Profile preview

MSC-Cytokine for Melanoma

Development stage: Preclinical
Lead developer: Kyttaro
Modality: Gene Therapies, Stem Cell Therapies → Cell Therapies
Administration: Intratumoral, Intravenous, Subcutaneous

Overview

**MSC-Cytokine for Melanoma** is an early research-stage engineered mesenchymal stromal cell therapy from Kyttaro Therapeutics. The product consists of genetically modified mesenchymal stromal cells designed to secrete interleukin-7 and interleukin-12, using the cells as a tumor-directed cytokine-delivery vehicle intended to stimulate antitumor immune activity in melanoma. The Kyttaro pipeline lists the melanoma program as R&D-stage; no clinical trial, dose regimen, route of administration, or manufacturing partner was identified in the provided public-source context.

Other names: MSC-Cyt (IL-7/IL-12)

Targets

IL7R (Interleukin-7 Receptor)IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on MSC-Cytokine for Melanoma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSC-Cytokine for Melanoma.

Explore the full profile